Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsClinico-microbiological profile of urinary tract infection in south IndiaDetermination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.Transrectal prostate biopsy-associated prophylaxis and infectious complications: report of a query to the emerging infections network of the infectious diseases society of america.Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.Fosfomycin: Uses and potentialities in veterinary medicinePerceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organismsThe continuing challenge of ESBLs.Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis.Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014)Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005-2006Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamasesEconomics of antibiotic resistance.Clinical significance of extended-spectrum beta-lactamases.Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study.Clinical Efficacy of Ertapenem for Recurrent Cystitis Caused by Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli in Female OutpatientsComparative Evaluation of Fosfomycin Activity with other Antimicrobial Agents against E.coli Isolates from Urinary Tract Infections.Tigecycline treatment for urinary tract infections: case report and literature review.Revisiting "older" antimicrobials in the era of multidrug resistance.Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.Aetiology and antibiotic resistance issues regarding urological procedures.Role of old antimicrobial agents in the management of urinary tract infection.Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.Fosfomycin tromethamine for the Treatment of Cystitis in Abdominal Solid Organ Transplant Recipients With Renal Dysfunction.Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae.Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli.Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Fosfomycin for the Treatment of Cystitis in the Abdominal Solid Organ Transplant Population.High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden.
P2860
Q21131083-639BFAA6-0FD5-4262-8C55-D18E5AB83915Q35030163-BDB4742E-6AE7-4CC5-B1B8-C311F9285EDBQ35214110-682AC3C5-322A-463C-8636-C338173678A4Q35628211-1F0C4240-FD78-4766-8B5C-9C9112866940Q36160749-E9ED9BC3-EE77-4BD1-9781-3A47EE8BEA85Q36239060-C094A1B4-9F24-41AD-9704-AB041E66EC06Q36298973-858F2C28-919D-42EA-94B8-B7E807E84381Q36449603-1E236E8F-34D0-4F6E-9A9C-4B78E552A5B1Q36644918-E676C3E6-7CE2-47A1-9F01-018684D8C277Q36684974-C76D6F18-C9E1-4255-B13A-A61A80F6FBB5Q36736995-0662ADE4-02C1-45E6-9719-D0B83987D183Q37115833-BBE52228-15E7-4B21-AF06-BCA61C5F0FBCQ37228745-392DBEFF-3855-45F6-B64A-790FE731B600Q37291354-6848E11D-C599-4D75-B7B8-6368600704B7Q37374128-D332E688-15D7-47D7-9D23-DB722540CA47Q37705545-C0154AAD-BBCF-4C46-92DA-05FEFA59E746Q37734217-AFFAE6B5-1C83-498C-82CE-F6C6C5CBAB37Q37899640-CD854D7E-63A1-445C-AAAE-ACED39742F40Q37933412-CE4E396A-C761-49A2-A8C9-DB88503EF33DQ38160759-FC22BA8A-7834-4C2F-96BC-95CFD137CB36Q38208281-4B892AA2-740D-44B6-B50F-62A840A1C22CQ38253257-D2B3A6B2-C815-4611-B802-C1D17A7D7984Q38832723-002B5311-C491-4125-95F4-20982E365236Q38849466-735732DC-4AB7-4486-B7D7-5F7BFB3E88DDQ39704722-F0F040A4-CD1A-4FF2-8180-D4AF93A2C6A5Q40166194-5E21628A-3A6F-4B3F-80B1-401457A6E48FQ40210176-978CCCA5-3156-4728-8C1D-071AE4A667BDQ40341858-326846C2-786D-463E-AF28-5679102B4898Q40595790-D60EC377-6B04-4494-8790-28C9B908FF52Q40810228-E3E22370-056C-4B3D-893B-BC9A00EF0619Q40886408-489335BC-63C9-46DB-BFC6-8D4A14FEB57DQ42102558-9DB1DDC7-B1D9-499B-84F2-7AB83EB72A53Q42261308-A3456882-59AD-4346-937E-4D9E9ADB0D71Q46286730-34869C71-7A8D-4184-98D1-DEB2C33BA02AQ46705551-16FC39D5-62D5-4C81-ADC6-77B4B335CECAQ48357071-ABD85192-162F-47C8-A7AF-CC766869AC5BQ52695014-52FE9993-067B-45F1-AF39-D9891473DDB9Q53747485-1CCF08FA-AEA9-4B19-BE58-B436A58923E0Q54324569-385A2D0F-A0E2-4620-BBC6-70FCFBA81ABA
P2860
Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Fosfomycin in the treatment of ...... ower urinary tract infections.
@en
type
label
Fosfomycin in the treatment of ...... ower urinary tract infections.
@en
prefLabel
Fosfomycin in the treatment of ...... ower urinary tract infections.
@en
P2093
P1476
Fosfomycin in the treatment of ...... ower urinary tract infections.
@en
P2093
Husnu Pullukcu
Meltem Tasbakan
Oguz Resat Sipahi
Sercan Ulusoy
Sohret Aydemir
Tansu Yamazhan
P356
10.1016/J.IJANTIMICAG.2006.08.039
P577
2007-01-01T00:00:00Z